Phase 3 Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with locally advanced squamous cell carcinoma (a specific type of cancer) in one of these areas: the oropharynx (back of the throat), hypopharynx (lower throat), oral cavity (mouth), or larynx (voice box), confirmed by a tissue or cell sample.
- People whose cancer has not spread to other parts of the body, and has been classified as Stage III, Stage IVA, or Stage IVB according to a standard cancer staging system (the 8th edition AJCC system).
- People who have already completed a full course of combined chemotherapy and radiation treatment (given together) aimed at curing the cancer, before entering the trial.
Who may not be able to join:
- People whose head and neck cancer started in a different location than those listed above — for example, the nasopharynx (upper throat behind the nose) or salivary glands — or whose cancer type is not squamous cell carcinoma, or where the original location of the cancer is unknown.
- People who have more than one primary (original) cancer tumour.
- People whose cancer was surgically removed before receiving the combined chemotherapy and radiation treatment.
- People whose cancer has already come back (recurred) by the time of the screening assessment.
- People who received radiation treatment on its own (without chemotherapy) as their main treatment for this cancer.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert Haddad, MD, Dana Farber Cancer Institute Massachusetts, USA
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free Survival (PFS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.